PlainPill

Vsl#3

The short answer. There isn't much data on Vsl#3 yet — 13 mentions, 4 with a clear outcome — so treat these numbers as anecdotal. It is most often used for digestion: 100% of 5 reports say that improved. It is well studied — 25 meta-analyses on PubMed.

What users report
100%helped4 reports · few reports
4 helped0 mixed0 didn't help

From 13 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
25
meta-analyses
52
RCTs
403
papers

What Vsl#3 does, according to users

Of the people who reported each effect, the share who said it got better.

2 more with fewer than 3 reports
betterno changeworse

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 25 meta-analyses on PubMed ↗ · 52 randomized trials ↗

Neurogastroenterol Motil · 2018 · Meta-analysis / systematic review
Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome

Conclusion: In this systematic review and meta-analysis, there was a trend toward improvement in overall response with VSL#3, but no clear evidence effectiveness for IBS. However, the number and sample sizes of the trials are small and the overall quality of evidence for 3 of the 5 outcomes was low. Larger trials evaluating validated endpoints in well-defined IBS patients are warranted.

PubMed 30069978 ↗
Benef Microbes · 2018 · Meta-analysis / systematic review
Mind the gut: probiotics in paediatric neurogastroenterology

Conclusion: Efficacy and safety of other strains or beneficial effects in other conditions still need to be proven, as probiotic properties are strain-specific, and data cannot be extrapolated to other brain-gut or mood diseases or to other probiotics of the same or different species. To transform the use of probiotics from a tempting suggestion to a promising treatment modality in neurogastroenterological disorders more accurate differentiation of the efficacy-proven strains, clarification of dose, duration, and outcome and a careful selection of the target patients are still necessary.

PubMed 30198327 ↗
Registered clinical trials

79 human trials on ClinicalTrials.gov test Vsl#3 — 38 completed, 2 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

US government research funding (NIH)

NIH has funded 4 research projects with Vsl#3 in the title, $631,870 in total (2004–2011). NIH RePORTER ↗

Dosage people report

As stated by users — not a recommendation. Follow the label or your doctor.

No doses stated in the reports so far.

Reported side effects

How often each side effect came up across all reports.

No side effects reported so far.

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“I started taking VSL#3 couple of weeks ago... there's been a mild, but perceptible increase in just overall 'getting things done'.”
HelpedRead the discussion ↗
“I take VSL #3 prescription grade (double strength) twice daily for over two years. My stomach feels better (I have chrohns), but that's it.”
Read the discussion ↗
“As a sufferer of Ulcerative Colitis, I can say that VSL#3 probiotic has done wonders for me.”
HelpedRead the discussion ↗
Top discussions (5)

Other options for digestion

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate